BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 26721366)

  • 1. Pioglitazone, an anti-diabetic drug requires sustained MAPK activation for its anti-tumor activity in MCF7 breast cancer cells, independent of PPAR-γ pathway.
    Kole L; Sarkar M; Deb A; Giri B
    Pharmacol Rep; 2016 Feb; 68(1):144-54. PubMed ID: 26721366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pioglitazone induces cell growth arrest and activates mitochondrial apoptosis in human uterine leiomyosarcoma cells by a peroxisome proliferator-activated receptor γ-independent mechanism.
    Lützen U; Zhao Y; Lucht K; Zuhayra M; Marx M; Cascorbi I; Culman J
    Naunyn Schmiedebergs Arch Pharmacol; 2017 Jan; 390(1):37-48. PubMed ID: 27664035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peroxisome proliferator-activated receptor-gamma ligands inhibit TGF-beta 1-induced fibronectin expression in glomerular mesangial cells.
    Guo B; Koya D; Isono M; Sugimoto T; Kashiwagi A; Haneda M
    Diabetes; 2004 Jan; 53(1):200-8. PubMed ID: 14693716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pioglitazone limits myocardial infarct size, activates Akt, and upregulates cPLA2 and COX-2 in a PPAR-γ-independent manner.
    Birnbaum Y; Long B; Qian J; Perez-Polo JR; Ye Y
    Basic Res Cardiol; 2011 May; 106(3):431-46. PubMed ID: 21360043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pioglitazone, a PPARγ agonist, attenuates PDGF-induced vascular smooth muscle cell proliferation through AMPK-dependent and AMPK-independent inhibition of mTOR/p70S6K and ERK signaling.
    Osman I; Segar L
    Biochem Pharmacol; 2016 Feb; 101():54-70. PubMed ID: 26643070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A rapid, PPAR-gamma-dependent effect of pioglitazone on the phosphorylation of MYPT.
    Atkins KB; Irey B; Xiang N; Brosius FC
    Am J Physiol Cell Physiol; 2009 May; 296(5):C1151-61. PubMed ID: 19261909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of peroxisome proliferator-activated receptor gamma in mammary epithelial cells upregulates the expression of tumor suppressor Cyld to mediate growth inhibition and anti-inflammatory effects.
    Pseftogas A; Gonidas C; Mosialos G
    Int J Biochem Cell Biol; 2017 Jan; 82():49-56. PubMed ID: 27865894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pioglitazone prevents hyperglycemia induced decrease of AdipoR1 and AdipoR2 in coronary arteries and coronary VSMCs.
    Shen X; Li H; Li W; Wu X; Ding X
    Mol Cell Endocrinol; 2012 Nov; 363(1-2):27-35. PubMed ID: 22820128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPAR-γ agonist pioglitazone regulates dendritic cells immunogenicity mediated by DC-SIGN via the MAPK and NF-κB pathways.
    Zhu W; Yan H; Li S; Nie W; Fan F; Zhu J
    Int Immunopharmacol; 2016 Dec; 41():24-34. PubMed ID: 27792919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PPARγ Agonist Pioglitazone in Combination With Cisplatinum Arrests a Chemotherapy-resistant Osteosarcoma PDOX Model.
    Higuchi T; Yamamoto J; Sugisawa N; Tashiro Y; Nishino H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Cancer Genomics Proteomics; 2020; 17(1):35-40. PubMed ID: 31882549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects.
    Yoshizumi T; Ohta T; Ninomiya I; Terada I; Fushida S; Fujimura T; Nishimura G; Shimizu K; Yi S; Miwa K
    Int J Oncol; 2004 Sep; 25(3):631-9. PubMed ID: 15289864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
    Bajaj M; Suraamornkul S; Hardies LJ; Glass L; Musi N; DeFronzo RA
    Diabetologia; 2007 Aug; 50(8):1723-31. PubMed ID: 17520238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes.
    Dello Russo C; Gavrilyuk V; Weinberg G; Almeida A; Bolanos JP; Palmer J; Pelligrino D; Galea E; Feinstein DL
    J Biol Chem; 2003 Feb; 278(8):5828-36. PubMed ID: 12486128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peroxisome proliferator-activated receptor γ agonist suppresses mast cell maturation and induces apoptosis.
    Zhang Y; Li X; Fang S; Zhu Z; Yao M; Ying L; Zhu L; Ma Z; Wang W
    Mol Med Rep; 2017 Aug; 16(2):1793-1800. PubMed ID: 28656266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Peroxisome proliferation-activated receptor-gamma ligands ameliorate autoimmune myocarditis associated with inhibition of T cell immunity].
    Yuan ZY; Liu Y; Liu Y; Zhang JJ; Kishimoto C; Liu ZQ
    Zhonghua Yi Xue Za Zhi; 2003 Dec; 83(23):2067-72. PubMed ID: 14703419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peroxisome proliferator-activated receptor-gamma ligands for the treatment of breast cancer.
    Fenner MH; Elstner E
    Expert Opin Investig Drugs; 2005 Jun; 14(6):557-68. PubMed ID: 16004588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation.
    Ohga S; Shikata K; Yozai K; Okada S; Ogawa D; Usui H; Wada J; Shikata Y; Makino H
    Am J Physiol Renal Physiol; 2007 Apr; 292(4):F1141-50. PubMed ID: 17190910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pioglitazone inhibits homocysteine-induced migration of vascular smooth muscle cells through a peroxisome proliferator-activated receptor gamma-independent mechanism.
    Li L; Gao PJ; Xi R; Wu CF; Zhu DL; Yan J; Lu GP
    Clin Exp Pharmacol Physiol; 2008 Dec; 35(12):1471-6. PubMed ID: 18759864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pioglitazone does not improve insulin signaling in mice with GH over-expression.
    Gesing A; Bartke A; Masternak MM
    J Endocrinol; 2013 Nov; 219(2):109-17. PubMed ID: 23946430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Troglitazone and pioglitazone interactions via PPAR-gamma-independent and -dependent pathways in regulating physiological responses in renal tubule-derived cell lines.
    Turturro F; Oliver R; Friday E; Nissim I; Welbourne T
    Am J Physiol Cell Physiol; 2007 Mar; 292(3):C1137-46. PubMed ID: 17065204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.